In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue SUPPL. B, 1997, Pages 15-22

  Rolston, Kenneth V L ^a   Ho, Dah H ^a   Leblanc, Barbara ^a   Streeter, Harriet ^a   Dvorak, Tanya ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; SPARFLOXACIN; TROVAFLOXACIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS CEREUS; CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; LISTERIA MONOCYTOGENES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0030805570     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.suppl_2.15     Document Type: Article

References (16)

1. Gooding, B. B. & Jones, R. N. (1993). In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 37, 349-53.
2. Neu, H. C. & Chin, N. X. (1994). In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy 38, 2615-22.
3. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C. (1994). Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacilltntazobactam, against 489 anaerobes. Antimicrobial Agents and Chemotherapy 38, 2471-6.
4. Knapp, J. S., Neal, S. W., Parekh, M. C. & Rice, R. J. (1995). In vitro activity of a new fluoroquinotone, CP-99,219, against strains of Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy 39, 987-9.
5. Chan, C. C., Oppenheim, B. A., Anderson, H., Swindell, R. & Scarffe, J. H. (1989). Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrobial Agents and Chemotherapy 33, 87-91.
6. Karp, J. E., Merz, W. G., Hendricksen, C., Laughon, B., Redden, T., Bamberger, B. J. et al. (1987). Oral norfloxacin for prevention of Gram-negative bacterial infections in patients with acute leukaemia and granulocytopenia. A randomized, doubleblind, placebo-controlled trial. Annals of Internal Medicine 106, 1-7.
7. National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Third Edition. Approved Standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, PA.
8. Eliopoulos, G. M., Klimm, K., Eliopoulos, C. T., Ferraro, M. J. & Moellering, R. C. (1993). In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 37, 366-70.
9. Dekker, A. W., Rosenberg-Arksa, M. & Verhoef, J. (1987). Infection prophylaxis in acute leukaemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Annals of Internal Medicine 106, 7-11.
10. Winston, D. J., Ho, W. G., Champlin, R. E., Karp, J., Bartlett, J., Finley, R. S. et al. (1987). Norfloxacin for prevention of bacterial infections in granulocytopenic patients. American Journal of Medicine 82, Suppl. 6B, 40-6.
11. Flaherty, J. P., Waitley, D., Edlin, B., George, D., Arnow, P., O'Keefe, P. et al. (1989). Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. American Journal of Medicine 87, Suppl. 5A, 278S-82S.
12. Rolston, K. V. I., Haron, E., Cunningham, C. & Bodey, G. P. (1989). Intravenous ciprofloxacin for infections in cancer patients. American Journal of Medicine 87, Suppl. 5A, 216S-8S.
13. Rubenstein, E. B., Rolston, K., Benjamin, R. S., Loewy, J., Escalante, C., Manzullo, E. et al. (1993). Outpatient treatment of febrile episodes in low-risk patients with cancer. Cancer 71, 3640-6.
14. Malik, I. A., Khan, W. A., Aziz, Z. & Karim, M. (1994). Selfadministered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. Clinical Infectious Diseases 19, 522-7.
15. Malik, I. A., Khan, W. A., Karim, M., Aziz, Z. & Khan, M. A. (1995). Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. American Journal of Medicine 98, 224-31.
16. Vartivarian, S., Anaissie, E., Bodey, G., Sprigg, H. & Rolston, K. (1994). A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrobial Agents and Chemotherapy 38, 624-7.